Cynthia Louise Miller, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphedema | 16 | 2016 | 523 | 1.730 |
Why?
|
| Mastectomy | 8 | 2016 | 1818 | 0.910 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2014 | 732 | 0.640 |
Why?
|
| Breast Neoplasms | 18 | 2016 | 20982 | 0.570 |
Why?
|
| Camptothecin | 1 | 2017 | 591 | 0.450 |
Why?
|
| Coronary Artery Bypass | 1 | 2022 | 2193 | 0.430 |
Why?
|
| Breast Implantation | 1 | 2016 | 219 | 0.430 |
Why?
|
| Lung Transplantation | 1 | 2022 | 1307 | 0.420 |
Why?
|
| Mammary Glands, Human | 1 | 2014 | 202 | 0.410 |
Why?
|
| Interleukin-6 | 1 | 2022 | 3210 | 0.410 |
Why?
|
| Arm | 6 | 2016 | 589 | 0.410 |
Why?
|
| Graft Rejection | 1 | 2022 | 4481 | 0.320 |
Why?
|
| Heart Transplantation | 1 | 2022 | 3258 | 0.320 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2016 | 926 | 0.310 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 1084 | 0.310 |
Why?
|
| Radiotherapy | 1 | 2014 | 1499 | 0.280 |
Why?
|
| Lymph Node Excision | 5 | 2014 | 1270 | 0.250 |
Why?
|
| Mammography | 1 | 2016 | 2430 | 0.240 |
Why?
|
| Lymphatic Irradiation | 2 | 2015 | 115 | 0.230 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4309 | 0.190 |
Why?
|
| Sternotomy | 1 | 2022 | 128 | 0.190 |
Why?
|
| Postoperative Complications | 4 | 2016 | 15637 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11733 | 0.170 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 12052 | 0.170 |
Why?
|
| Axilla | 4 | 2014 | 624 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 6919 | 0.140 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 407 | 0.130 |
Why?
|
| Leucovorin | 1 | 2017 | 643 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 2827 | 0.110 |
Why?
|
| Antineoplastic Protocols | 1 | 2014 | 48 | 0.110 |
Why?
|
| Hepatectomy | 1 | 2017 | 557 | 0.110 |
Why?
|
| Cellulitis | 1 | 2015 | 208 | 0.110 |
Why?
|
| Transplantation, Homologous | 1 | 2022 | 4822 | 0.110 |
Why?
|
| Aged, 80 and over | 12 | 2016 | 58952 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2022 | 2307 | 0.110 |
Why?
|
| Aged | 15 | 2017 | 169288 | 0.100 |
Why?
|
| Fluorouracil | 1 | 2017 | 1642 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 12474 | 0.100 |
Why?
|
| Risk Factors | 10 | 2016 | 74239 | 0.100 |
Why?
|
| Middle Aged | 16 | 2017 | 220853 | 0.090 |
Why?
|
| Adult | 16 | 2017 | 221119 | 0.090 |
Why?
|
| Postoperative Period | 2 | 2013 | 1818 | 0.090 |
Why?
|
| Preventive Medicine | 1 | 2012 | 245 | 0.090 |
Why?
|
| Mastectomy, Segmental | 1 | 2016 | 955 | 0.090 |
Why?
|
| Breast Diseases | 1 | 2014 | 443 | 0.090 |
Why?
|
| Prospective Studies | 10 | 2016 | 54435 | 0.080 |
Why?
|
| Incidence | 4 | 2016 | 21365 | 0.080 |
Why?
|
| Heart | 1 | 2022 | 4431 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2022 | 4190 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2015 | 3512 | 0.080 |
Why?
|
| Female | 20 | 2017 | 392544 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1008 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2022 | 64681 | 0.070 |
Why?
|
| Cytokines | 1 | 2022 | 7386 | 0.070 |
Why?
|
| Humans | 22 | 2022 | 761208 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 6819 | 0.070 |
Why?
|
| Breast | 1 | 2016 | 1964 | 0.070 |
Why?
|
| Young Adult | 6 | 2015 | 59221 | 0.060 |
Why?
|
| Fear | 1 | 2014 | 1477 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2014 | 2026 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6486 | 0.060 |
Why?
|
| Body Mass Index | 4 | 2014 | 12952 | 0.050 |
Why?
|
| Quality of Life | 5 | 2015 | 13367 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 39126 | 0.040 |
Why?
|
| Prognosis | 2 | 2017 | 29687 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 20588 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2015 | 6223 | 0.030 |
Why?
|
| Phlebotomy | 1 | 2015 | 137 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 9278 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2014 | 41496 | 0.030 |
Why?
|
| Arm Injuries | 1 | 2015 | 156 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 551 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 832 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 633 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 8519 | 0.020 |
Why?
|
| Taxoids | 1 | 2015 | 668 | 0.020 |
Why?
|
| Time Factors | 3 | 2015 | 39957 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 2420 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 80674 | 0.020 |
Why?
|
| Motor Activity | 1 | 2015 | 2712 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 2317 | 0.010 |
Why?
|
| Patient Selection | 1 | 2014 | 4246 | 0.010 |
Why?
|
| Self Report | 1 | 2013 | 3727 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14675 | 0.010 |
Why?
|
| Male | 1 | 2017 | 360693 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 3198 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 11119 | 0.010 |
Why?
|
| Age Factors | 1 | 2014 | 18384 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 13511 | 0.010 |
Why?
|